Antibody-drug Conjugates
- Name
- Antibody-drug Conjugates
- Accession Number
- DBCAT005781
- Description
Not Available
- Drugs
Drug Drug Description Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Polatuzumab vedotin A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma. Sacituzumab govitecan Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis. Enfortumab vedotin An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Belantamab mafodotin An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Indusatumab vedotin Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others. Indatuximab ravtansine Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma). Anetumab ravtansine Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer). Cantuzumab ravtansine Investigated for use/treatment in gastric cancer. Coltuximab ravtansine Investigated for use/treatment in lymphoma (non-hodgkin's). Disitamab vedotin Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers. Enapotamab vedotin Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors). Tamrintamab pamozirine Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3. Lorvotuzumab mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others. Cantuzumab mertansine Not Annotated Mirvetuximab soravtansine A folate receptor alpha-directed antibody and microtubule inhibitor conjugate used to treat folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Loncastuximab tesirine An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas. - Drugs & Drug Targets